Screener
Halozyme Therapeutics HALO Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's net income?
- Halozyme Therapeutics (HALO) reported net income of $229.91M in Q2 2026.
- How has Halozyme Therapeutics's net income changed year-over-year?
- Halozyme Therapeutics's net income increased by 39.2% year-over-year, from $165.16M to $229.91M.
- What is the long-term trend for Halozyme Therapeutics's net income?
- Over 3 years (2021 to 2024), Halozyme Therapeutics's net income has grown at a 3.3% compound annual growth rate (CAGR), from $402.71M to $444.09M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Halozyme Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude